Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | HTT | P42858 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885963 | 0.82 | TAS1R3 (0.60) | NPC1RAB9AHTTALDH1A1MAPT | |
| SCHEMBL5067154 | 0.82 | NPC1 (0.58) | NPC1RAB9AHTTALDH1A1MAPT | |
| SCHEMBL3276738 | 0.80 | NPC1 (0.60) | NPC1RAB9AHTTALDH1A1MAPT | |
| SCHEMBL13055719 | 0.77 | P2RX1 (0.50) | NPC1RAB9AHTTALDH1A1MAPT | |
| SCHEMBL744173 | 0.77 | STAT3 (0.60) | NPC1RAB9AHTTALDH1A1KDM4E | |
| SCHEMBL13056040 | 0.76 | RXFP1 (0.54) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL9796220 | 0.75 | CA2 (0.71) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13056093 | 0.75 | P2RX1 (0.51) | NPC1RAB9AHTTALDH1A1MAPT | |
| SCHEMBL7693424 | 0.74 | EGLN1 (0.62) | NPC1RAB9AHTTALDH1A1MAPT | |
| SCHEMBL11875075 | 0.74 | NPC1 (0.62) | NPC1RAB9AHTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47786-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES L.C. (US) | 2019-12-31 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| EP-3078377-A2 | NITAZOXANIDE AND TIZOXANIDE AS ANTI-VIRAL AGENTS | Romark Laboratories, L.C. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9126992-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2010132404-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | NPC1 911/4885RAB9A 3691/4885HTT 4053/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | NPC1 4422/4885RAB9A 2827/4885HTT 600/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | NPC1 1218/4885RAB9A 4418/4885HTT 3795/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | NPC1 4407/4885RAB9A 2536/4885HTT 700/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | NPC1 978/4885RAB9A 1124/4885HTT 3223/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | NPC1 978/4885RAB9A 1124/4885HTT 3223/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | NPC1 313/4885RAB9A 3333/4885HTT 14/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | NPC1 429/4885RAB9A 2290/4885HTT 3533/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | NPC1 4521/4885RAB9A 2704/4885HTT 532/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | NPC1 4551/4885RAB9A 2770/4885HTT 509/4885 |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | HDHD5, HAVCR2, AADAC | NPC1 338/4885RAB9A 1886/4885HTT 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.